Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)
Clinical trial NCT03302234 · COMPLETED
Trial details
- NCT number
- NCT03302234
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-14
- Primary completion
- 2020-09-01
- Enrollment
- 568
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.